Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Osimertinib + Carotuximab for Lung Cancer
Recruiting2 awardsPhase 1
Los Angeles, California
This trial is testing a combination of two drugs, osimertinib and carotuximab, to treat advanced EGFR-mutated non-small cell lung cancer. The goal is to find the maximum tolerated dose of the combination by measuring the number of dose-limiting toxicities. Secondary objectives include evaluating the rate of objective response, duration of response, progression-free survival, and disease control rate.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.